

DAFTAR PUSTAKA

- Afonso, A.S.M., Verhamme, K.M.C., Sturkenboom, M.C.J.M., dan Brusselle, G.G.O., 2011. COPD in the general population: Prevalence, incidence and survival. *Respiratory Medicine*, **105**: 1872–1884.
- Alldredge, B.K., Corelli R.L., Ernst, M.E., Guglielmo, B.J., Jacobson P.A., Kradjan, W.A., dkk. 2013, *Koda-Kimble & Young's Applied Therapeutics The Clinical Use of Drugs 10th Edition*, Philadelphia: Lippincott Williams & Wilkins.
- Anthonisen, N.R., Connett, J.E., Kiley, J.P., Altose, M.D., Bailey, W.C., Buist, A.S., dkk., 1994. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. *JAMA*, **272**: 1497–1505.
- Bernabeu-Mora, R., García-Guillamón, G., Valera-Novella, E., Giménez-Giménez, L.M., Escolar-Reina, P., dan Medina-Mirapeix, F., 2017. Frailty is a predictive factor of readmission within 90 days of hospitalization for acute exacerbations of chronic obstructive pulmonary disease: a longitudinal study. *Ther Adv Respir Dis*, **11**: 383–392.
- Blair, A., Sathyanarayanan, S., dan Benjamin, B., 2019. Retrospective, matched cohort study of the effectiveness of common COPD drug treatments on 30-day readmissions.
- Bollmeier, S.G. dan Hartmann, A.P., 2020. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. *Am J Health Syst Pharm*, **77**: 259–268.
- Blee, J., Roux, R.K., Gautreaux, S., Sherer, J.T., dan Garey, K.W., 2015. Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. *American Journal of Health-System Pharmacy*, **72**: 1204–1208.
- Burns, M.A.C., Schwinghammer, T.L., Malone, P.M., Kolesar, J.M., Lee, K.C., Bookstaver, P.B., 2019, *Paracotherapy Principle & Practice 5th Edition*, New York: McGraw-Hill Education.
- Celi, A., Latorre, M., Paggiaro, P., dan Pistelli, R., 2021. Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. *Ther Adv Chronic Dis*, **14**: 20406223211014028.
- Chrystyn, H., Price, D.B., Molimard, M., Haughney, J., Bosnic-Anticevich, S., Lavorini, F., dkk., 2016. Comparison of serious inhaler technique errors

made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study. *BMC Pulm Med*, **16**: 12.

Davies, L., Angus, R.M., dan Calverley, P.M., 1999. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet (London, England)*, **354**: 456–460.

DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., Ellingrod, V., 2020, *Pharmacotherapy A Pathophysiologic Approach 11th Edition*, New York: McGraw Hill.

Domej, W., Oettl, K., dan Renner, W., 2014. Oxidative stress and free radicals in COPD--implications and relevance for treatment. *Int J Chron Obstruct Pulmon Dis*, **9**: 1207–1224.

Ek, A., Larsson, K., Siljerud, S., dan Palmberg, L., 1999. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. *Allergy*, **54**: 691–699.

Fan, V.S., Gaziano, J.M., Lew, R., Bourbeau, J., Adams, S.G., Leatherman, S., dkk., 2012. A Comprehensive Care Management Program to Prevent Chronic Obstructive Pulmonary Disease Hospitalizations. *Ann Intern Med*, **156**: 673–683.

Fenton, C. dan Keating, G.M., 2004. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease. *Drugs*, **64**: 1975–1996.

Global Initiative for Chronic Obstructive Lung Disease, 2020, *Pocket Guide to COPD Diagnosis, Management, and Prevention A Guide for Health Care Professionals 2020 Edition*, Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc.

Goel, M.K., Khanna, P., dan Kishore, J., 2010. Understanding survival analysis: Kaplan-Meier estimate. *International Journal of Ayurveda Research*, **1**: 274–278.

Gudmundsson, G., Gislason, T., Janson, C., Lindberg, E., Hallin, R., Ulrik, C.S., dkk., 2005. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. *European Respiratory Journal*, **26**: 414–419.

Gulati, S. dan Wells, J.M., 2017. Bringing stability to the COPD patient: clinical and pharmacological considerations for frequent exacerbators. *Drugs*, **77**: 651–670.

- Halpin, D.M.G., Gray, J., Edwards, S.J., Morais, J., dan Singh, D., 2011. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. *International Journal of Clinical Practice*, **65**: 764–774.
- Harries, T.H., Thornton, H., Crichton, S., Schofield, P., Gilkes, A., dan White, P.T., 2017. Hospital readmissions for COPD: a retrospective longitudinal study. *NPJ Prim Care Respir Med*, **27**: 31.
- Huang, K., Guo, Y., Kang, J., An, L., Zheng, Z., Ma, L., dkk., 2019. The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China. *Ther Adv Respir Dis*, **13**: 1753466619853500.
- Janson, C., 2020. Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. *J Thorac Dis*, **12**: 1561.
- Kankaanranta, H., Harju, T., Kilpeläinen, M., Mazur, W., Lehto, J.T., Katajisto, M., dkk., 2015. Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines. *Basic Clin Pharmacol Toxicol*, **116**: 291–307.
- Kementerian Kesehatan Republik Indonesia, 2013, *Riset Kesehatan Dasar 2013*, Jakarta: Badan Penelitian Dan Pengembangan Kementerian Kesehatan RI.
- Kerstjens, H.A.M., Upham, J.W., dan Yang, I.A., 2019. Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease. *Journal of Thoracic Disease*, **11**: S2200–S2209.
- Ko, F.W., Chan, K.P., Hui, D.S., Goddard, J.R., Shaw, J.G., Reid, D.W., dkk., 2016. Acute exacerbation of COPD. *Respirology (Carlton, Vic.)*, **21**: 1152–1165.
- Kong, C.W. dan Wilkinson, T.M.A., 2020. Predicting and preventing hospital readmission for exacerbations of COPD. *ERJ Open Res*, **6**: 00325–02019.
- Larsson, K., Janson, C., Lisspers, K., Jørgensen, L., Stratelis, G., Telg, G., dkk., 2013. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. *Journal of Internal Medicine*, **273**: 584–594.
- Latorre, M., Novelli, F., Vagaggini, B., Braidò, F., Papi, A., Sanduzzi, A., dkk., 2015. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of

chronic obstructive pulmonary disease (COPD): Role of ICS. *Pulmonary Pharmacology & Therapeutics*, **30**: 44–50.

Lemeshow S., Hosmer D.W., Klar J., Lwanga S.K., dan Organization W.H., 1990. *Adequacy of sample size in health studies*. Chichester : Wiley.

Lewis, A., Torvinen, S., Dekhuijzen, P.N.R., Chrystyn, H., Watson, A.T., Blackney, M., dkk., 2016. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. *BMC Health Serv Res*, **16**: 251.

Mathioudakis, A.G., Janssens, W., Sivapalan, P., Singanayagam, A., Dransfield, M.T., Jensen, J.-U.S., dkk., 2020. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. *Thorax*, **75**: 520–527.

McGhan, R., Radcliff, T., Fish, R., Sutherland, E.R., Welsh, C., dan Make, B., 2007. Predictors of Rehospitalization and Death After a Severe Exacerbation of COPD. *Chest*, **132**: 1748–1755.

Mensing, M. dan Aalbers, R., 2007. Comparison and optimal use of fixed combinations in the management of COPD. *Int J Chron Obstruct Pulmon Dis*, **2**: 107–116.

Nannini, L.J., Poole, P., Milan, S.J., Holmes, R., dan Normansell, R., 2013. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, **2013**: CD003794.

Nannini, L.J., Poole, P., Milan, S.J., dan Kesterton, A., 2013. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, **2013**: CD006826.

Partridge, M.R., Schuermann, W., Beckman, O., Persson, T., dan Polanowski, T., 2009. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. *Therapeutic Advances in Respiratory Disease*, **3**: 147–157.

Perrone, V., Sangiorgi, D., Buda, S., dan Degli Esposti, L., 2016. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting. *Int J Chron Obstruct Pulmon Dis*, **11**: 2749–2755.

- Qureshi, H., Sharafkhaneh, A., dan Hanania, N.A., 2014. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. *Ther Adv Chronic Dis*, **5**: 212–227.
- Rinne, S.T., Graves, M.C., Bastian, L.A., Lindenauer, P.K., Wong, E.S., Hebert, P.L., dkk., 2017. Association Between Length of Stay and Readmission for COPD. *The American journal of managed care*, **23**: e253–e258.
- Roberts, M.H., Clerisme-Beaty, E., Kozma, C.M., Paris, A., Slaton, T., dan Mapel, D.W., 2016. A retrospective analysis to identify predictors of COPD-related rehospitalization. *BMC pulmonary medicine*, **16**: 68.
- Roede, B.M., Bresser, P., Prins, J.M., Schellevis, F., Verheij, T.J.M., dan Bindels, P.J.E., 2009. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. *European Respiratory Journal*, **33**: 282–288.
- Sharafkhaneh, A., Mattewal, A.S., Abraham, V.M., Dronavalli, G., dan Hanania, N.A., 2010. Budesonide/formoterol combination in COPD: a US perspective. *Int J Chron Obstruct Pulmon Dis*, **5**: 357–366.
- Silverman, E.K. dan Sandhaus, R.A., 2009. 'Alpha1-Antitrypsin Deficiency', , *n-clinical-practice*, <http://dx.doi.org/10.1056/NEJMcp0900449>. URL: <https://www.nejm.org/doi/10.1056/NEJMcp0900449> (diakses tanggal 10/5/2021).
- Sin, D.D. dan Tu, J.V., 2001. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **164**: 580–584.
- Soeroto, A.Y. dan Suryadinata, H., 2014. Penyakit Paru Obstruktif Kronik. *Am J Respir Crit Care Med*. 2014;187(4):347 - 65. 2., 6.
- Soriano, J.B., Kiri, V.A., Pride, N.B., dan Vestbo, J., 2003. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. *American Journal of Respiratory Medicine: Drugs, Devices, and Other Interventions*, **2**: 67–74.
- Soriano, J.B., Vestbo, J., Pride, N.B., Kiri, V., Maden, C., dan Maier, W.C., 2002. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. *European Respiratory Journal*, **20**: 819–825.
- Steer, J., Gibson, G.J., dan Bourke, S.C., 2010. Predicting outcomes following hospitalization for acute exacerbations of COPD. *QJM: An International Journal of Medicine*, **103**: 817–829.

- Tang, B., Wang, J., Luo, L., Li, Q., dan Huang, D., 2019. Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis. *International Journal of Chronic Obstructive Pulmonary Disease*, **14**: 757–766.
- Tashkin, D.P., 2020. Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. *Int J Chron Obstruct Pulmon Dis*, **15**: 3105–3122.
- Tashkin, D.P., Ohar, J.A., Koltun, A., Allan, R., dan Ward, J.K., 2021. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. *Pulmonary Medicine*, **2021**: 8881895.
- Tran, M., Xiang, P., Rascati, K.L., Stock, E.M., Godley, P.J., Coleman, A., dkk., 2016. Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission. *J Manag Care Spec Pharm*, **22**: 1186–1193.
- Tricco, A.C., Striffler, L., Veroniki, A.-A., Yazdi, F., Khan, P.A., Scott, A., dkk., 2015. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. *BMJ Open*, **5**: e009183.
- Vogelmeier, C.F., Román-Rodríguez, M., Singh, D., Han, M.K., Rodríguez-Roisin, R., dan Ferguson, G.T., 2020. Goals of COPD treatment: Focus on symptoms and exacerbations. *Respiratory Medicine*, **166**: 105938.
- Wang, Y., Xu, J., Meng, Y., Adcock, I.M., dan Yao, X., 2018. Role of inflammatory cells in airway remodeling in COPD. *Int J of Chron Obstruct Pulmon Dis*, **13**: 3341–3348.
- Westerik, J.A.M., Metting, E.I., van Boven, J.F.M., Tiersma, W., Kocks, J.W.H., dan Schermer, T.R., 2017. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. *Respiratory Research*, **18**: 31.
- Willard, K.S., Sullivan, J.B., Thomashow, B.M., Jones, C.S., Fromer, L., Yawn, B.P., dkk., 2016. The 2nd National COPD Readmissions Summit and Beyond: From Theory to Implementation. *Chronic Obstr Pulm Dis*, **3**: 778–790.
- Yao, Y., Zhou, J., Diao, X., dan Wang, S., 2019. Association between tumor necrosis factor- α and chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Ther Adv Respir Dis*, **13**: 1753466619866096.